(Q38748641)

6 September 2017

title

Antitumour actions of interferons: implications for cancer therapy (English)

1 reference

6 September 2017

3

1 reference

6 September 2017

Belinda S Parker

1

0 references

author name string

Jai Rautela

series ordinal

2

1 reference

6 September 2017

language of work or name

English

0 references

publication date

1 February 2016

1 reference

6 September 2017

published in

Nature Reviews Cancer

1 reference

6 September 2017

volume

16

1 reference

6 September 2017

issue

3

1 reference

6 September 2017

page(s)

131-144

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc.2016.14

6 September 2017

exact match

0 references

cites work

Fine tuning type I interferon responses

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon-lambda: a new addition to an old family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon-γ: an overview of signals, mechanisms and functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Constitutive type I interferon modulates homeostatic balance through tonic signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon-kappa, a novel type I interferon expressed in human keratinocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

IFN-zeta/ limitin: a member of type I IFN with mild lympho-myelosuppression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon-ε protects the female reproductive tract from viral and bacterial infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Soluble interferon-alpha receptor molecules are present in body fluids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Soluble IFN receptor potentiates in vivo type I IFN signaling and exacerbates TLR4-mediated septic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon-induced nuclear signalling by Jak protein tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Mechanisms of type-I- and type-II-interferon-mediated signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

INTERFEROME: the database of interferon regulated genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Toll-like receptors as interferon-regulated genes and their role in disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Dynamic control of type I IFN signalling by an integrated network of negative regulators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Crk at the quarter century mark: perspectives in signaling and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Crk adaptor proteins act as key signaling integrators for breast tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Mechanisms of Interferon-alpha induced apoptosis in malignant cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Synergy between RA and TLR3 promotes type I IFN-dependent apoptosis through upregulation of TRAIL pathway in breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Inverse interference: how viruses fight the interferon system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Stochastic receptor expression determines cell fate upon interferon treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in athymic (nude) mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferons and their stimulated genes in the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Cancer; a biological approach. I. The processes of control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

The three Es of cancer immunoediting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Mechanism of the Antitumour Effect of Interferon in Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

A critical function for type I interferons in cancer immunoediting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Impaired IFN- Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Cross-presentation by dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Inflammatory cytokines as a third signal for T cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Regulatory T cells increase in breast cancer and in stage IV breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Regulatory T cells and breast cancer: implications for immunopathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Cellular responses to interferon-gamma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Augmentation of natural and antibody-dependent cell-mediated cytotoxicity by pure human leukocyte interferon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Innate lymphoid cells--a proposal for uniform nomenclature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Type I IFN contributes to NK cell homeostasis, activation, and antitumor function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Critical roles for IFN-β in lymphoid development, myelopoiesis, and tumor development: Links to tumor necrosis factor α

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Investigations of interferon-lambda for the treatment of cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Differential expression of STAT1 and p21 proteins predicts pancreatic cancer progression and prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferons and their antitumor properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Direct effects of type I interferons on cells of the immune system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Long-term outcomes and prognostic factors of high-risk malignant melanoma patients after surgery and adjuvant high-dose interferon treatment: a single-center experience.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Patient preferences for adjuvant interferon alfa-2b treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

The impact of PEGylation on biological therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Peginterferon α in the treatment of chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Trial Watch: Toll-like receptor agonists in oncological indications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Recombinant interferon in advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Recombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Clinical and immunological study of beta interferon by intramuscular route in patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Lack of response in nine patients with breast cancer treated with fibroblast interferon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Lymphoblastoid interferon in advanced breast cancer: a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Steroid receptor enhancement by natural interferon-beta in advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Effect of interferon alpha-2a on hormone receptor status in patients with advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Tamoxifen and alpha interferon in advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Tamoxifen and interferon-beta for the treatment of metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Changes in cytokine production of breast cancer patients treated with interferons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Combined effects of 13-cis-retinoic acid, tamoxifen and interferon on the growth of human breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Beta-interferon, retinoids and tamoxifen in metastatic breast cancer: long-term follow-up of a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon-beta, retinoids, and tamoxifen in the treatment of metastatic breast cancer: a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

The molecular basis for functional plasticity in type I interferon signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Cisplatin and recombinant alpha interferon in advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Subcutaneously Administered Recombinant Human Interleukin-2 and Interferon Alfa-2a for Advanced Breast Cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunologic parameters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Adjuvant treatment with polyadenylic-polyuridylic acid (Polya.Polyu) in operable breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Circulating tumor cells predict survival in early average-to-high risk breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

A pooled analysis of bone marrow micrometastasis in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Cancer immunotherapy: the interferon-alpha experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

The emerging role of immunosurveillance in dictating metastatic spread in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Systemic effects of local radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Immune modulation for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Systems biology of interferon responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Immunogenic cell death and DAMPs in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Calreticulin exposure dictates the immunogenicity of cancer cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon-α suppresses cAMP to disarm human regulatory T cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

IFN-alpha/beta enhances BCR-dependent B cell responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

IFN-dependent down-regulation of the NKG2D ligand H60 on tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon Induces Natural Killer Cell Blastogenesis In Vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Type I interferons keep activated T cells alive

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Natural killer cells in antiviral defense: function and regulation by innate cytokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Intrapleural application of human leukocyte interferon (HLI) in breast cancer patients with ipsilateral pleural carcinomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Recombinant gamma interferon in advanced breast cancer: a phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Phase II trial of recombinant beta (IFN-betaser) interferon in the treatment of metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: results of a multicentric phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.14

White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma

31 March 2020

1 reference

12 December 2020

Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells.

1 reference

12 December 2020

Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response

1 reference

12 December 2020

Overview of preclinical and clinical studies of interferon alfa-2b in combination with cytotoxic drugs.

1 reference

12 December 2020

Beta-interferon, retinoids and tamoxifen combination in advanced breast cancer

1 reference

12 December 2020

Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial

1 reference

12 December 2020

In vivo effect induced by interferon beta on steroid receptor status, cell kinetics and DNA ploidy in operable breast cancer patients

1 reference

12 December 2020

Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells

1 reference

12 December 2020

Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells.

1 reference

12 December 2020

Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer

1 reference

12 December 2020

Clinical trials using polyadenylic-polyuridylic acid as an adjuvant to surgery in treating different human tumors

1 reference

12 December 2020

Effect of natural beta-interferon on estrogen receptor mRNA of breast cancer cells

1 reference

12 December 2020

Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancer

1 reference

12 December 2020

Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer

1 reference

12 December 2020

Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer

1 reference

12 December 2020

Interferon in breast cancer

1 reference

12 December 2020

YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage

1 reference

12 December 2020

A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients

1 reference

12 December 2020

[An investigation of serum soluble interferon receptor levels in patients with renal cell carcinoma]

1 reference

12 December 2020

Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines

1 reference

12 December 2020

A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrence

1 reference

12 December 2020

Mechanisms of resistance off NSCLC to interferons.

1 reference

12 December 2020

Early phase II study of interferon-alpha and tumor necrosis factor-alpha combination in patients with advanced cancer

1 reference

12 December 2020

The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNalpha on pleomorphic sarcoma cells

1 reference

12 December 2020

Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment

1 reference

12 December 2020

A randomized trial of low doses of alpha interferon in patients with breast cancer

1 reference

12 December 2020

Natural interferon-beta and tamoxifen in hormone-resistant patients with advanced breast cancer

1 reference

12 December 2020

Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer

1 reference

12 December 2020

Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma

1 reference

12 December 2020

Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice

1 reference

12 December 2020

Immunological Surveillance in Neoplasia

1 reference

12 December 2020

The tumor suppressor function of STAT1 in breast cancer

1 reference

12 December 2020

A phase I clinical tolerance study of polyadenylic-polyuridylic acid in cancer patients

1 reference

12 December 2020

Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression.

1 reference

12 December 2020

Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC.2016.14

1 reference

Dimensions Publication ID

6 September 2017

1052569474

0 references

1 reference